This was in keeping with the post-hoc analysis of the AMPLE study demonstrating that in RA patients with highest baseline anti-CCP2 antibody concentrations there was a stronger correlation with better clinical response to abatacept compared with those with lower concentrations [15]. Here, AGBL2 is linked to rheumatoid arthritis.